Onkologie, Hämatologie - Daten und Informationen

Literatur zu Kapitel 8.10: Sekundäre akute myeloische Leukämie

Autor/en: A.A.N. Giagounidis, C. Aul
Letzte Änderung: 01.07.2008
  • Aksoy M.
    Benzene as a leukemogenic and carcinogenic agent.
    Am J Ind Med 1985a;8:9-20.

  • Aksoy M.
    Malignancies due to occupational exposure to benzene.
    Am J Ind Med 1985b;7:395-402.

  • Andersen MK et al.
    Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
    Haematologica 1998;83:483-488.

  • Andersen MK et al.
    Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
    Genes Chromosomes Cancer 2002;33:395-400.

  • Archimbaud E et al.
    Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Leukemia 1999;13:843-849.

  • Aul C, Gattermann, N, Schneider W.
    Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.
    Br J Haematol 1992;82:358-367.

  • Aul C et al.
    Increasing incidence of myelodysplastic syndromes: real or fictitious?
    Leuk Res 1998;22:93-100.

  • Beebe GW, Kato H, Land CE.
    Studies of the mortality of A-bomb survivors: 6. mortality and radiation dose, 1950-1974.
    Radiat Res 1978;75:138-201.

  • Estey EH.
    Prognosis and therapy of secondary myelodysplastic syndromes.
    Haematologica 1998;83:543-549.

  • Estey EH, Pierce S, Keating MJ.
    Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities.
    Haematologica 2000;85:246-249.

  • Godwin JE et al.
    A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
    Blood 1998;91:3607-3615.

  • Hann IM et al.
    Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
    Blood 1997;89:2311-2318.

  • Holmberg B, Lundberg P.
    Benzene: standards, occurrence, and exposure.
    Am J Ind Med 1985;7:375-383.

  • Kantarjian HM et al.
    Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.
    J Clin Oncol 1986;4:1748-1757.

  • Karp JE, Smith MA.
    The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention.
    Semin Oncol 1997;24:103-113.

  • Leith CP e al.
    Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
    Blood 1997;89:3323-3329.

  • Leone G et al.
    The incidence of secondary leukemias.
    Haematologica 1999;84:937-945.

  • Lowenberg B et al.
    Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
    Blood 1997;90:2952-2961.

  • Lowenberg B et al.
    Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    J Clin Oncol 1998;16:872-881.

  • Lubbert M, Minden M.
    Decitabine in acute myeloid leukemia.
    Semin Hematol 2005;42:38-42.

  • Moeller DW, Sun LS.
    Comparison of natural background dose rates for residents of the Amargosa Valley, NV, to those in Leadville, CO, and the states of Colorado and Nevada.
    Health Phys 2006;91:338-353.

  • Pedersen-Bjergaard J et al.
    Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
    Leukemia 1993;7:1975-1986.

  • Thirman MJ, Larson, RA.
    Therapy-related myeloid leukemia.
    Hematol Oncol Clin North Am 1996;10:293-320.

  • Toyota M et al.
    Methylation profiling in acute myeloid leukemia.
    Blood 2001;97:2823-2829.

  • Tubiana M et al.
    The debate on the use of linear no threshold for assessing the effects of low doses.
    J Radiol Prot 2006a;26:317-324.

  • Tubiana M et al.
    Recent reports on the effect of low doses of ionizing radiation and its dose-effect relationship.
    Radiat Environ Biophys 2006b;44:245-251.

  • Yin SN et al.
    Leukaemia in benzene workers: a retrospective cohort study.
    Br J Ind Med 1987;44:124-128.

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag" (Publikation als Buch)
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
und in Kooperation mit "Studien-Allianz Leukämie"
Deutscher Ärzte-Verlag  Studien-Allianz Leukämien
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: